determined in tissue culture using a GFP-based reporter assay for intact DNA repair 66 function 11 . For BRCA1 variants tested thus far, this assay has stratified the protein 67 function of known benign and pathogenic variants with high sensitivity and specificity A multiplexed assay to measure the effect of protein variants on homology-directed 93
DNA repair 94
The multiplexed HDR reporter assay is based on an assay developed by the Jasin 95 laboratory 11 . In this reporter assay, a site-specific double-stranded DNA break induced 96 by the I-SceI endonuclease results in conversion of a GFP-negative cell to GFP-positive 97 if the HDR pathway is intact (Fig. 1a) . Loss of BRCA1 activity (e.g. by depletion with 98 siRNA) results in cells that cannot repair the GFP through HDR from the donor template.
99
We previously used this assay [13] [14] [15] 18 to test the capacity of 158 individual BRCA1 100 missense variants to rescue the loss of endogenous BRCA1. BRCA1 HDR function with 101 these individual assays demonstrates 100% specificity and 91.6% sensitivity for 102 predicting the cancer risk associated with variants with established interpretations (n = 103 43, Supplementary  Fig.  1 ). The one known pathogenic variant misidentified as benign, 104 R71G, affects splicing, rather than protein function 19 , and therefore could not have been 105
classified correctly with an assay that expresses variants within a cDNA copy of BRCA1.
106
Given this functional assay's established specificity and sensitivity for predicting clinical 107 pathogenicity, we sought to convert it to a multiplexed format in order to generate high-108 confidence predictions for hundreds of BRCA1 variants in a single experiment.
110
As a pilot version of a multiplexed HDR reporter assay (Fig.  1b) , we prepared a pool of 111 plasmids containing the wild-type (WT) BRCA1 and 15 BRCA1 variants that had been 112 tested individually. We integrated these plasmids en masse into the HeLa-derived HDR 113
reporter cell line, which we had engineered to contain a single recombinase-based 114 landing pad (HeLa-DR-FRT, Methods). Though it is low efficiency, we used a 115 recombinase-based system to ensure that only a single variant would be integrated into 116 a common site in each cell, ensuring consistent expression levels and avoiding 117 complications associated with lentiviruses, e.g. variable integration sites and template 118 switching 20 . 119 120
After selecting for cells containing an integrated BRCA1 variant, we performed the three 121 steps of the HDR reporter assay. First, endogenous BRCA1 was depleted with an siRNA 122 targeting the 3' untranslated region of the endogenous BRCA1 mRNA. Second, I-SceI 123 was expressed to generate a double-strand break in the broken GFP reporter. Third, after 124 allowing sufficient time for double-stranded DNA break repair, cells were sorted into GFP-125 positive and GFP-negative populations. The BRCA1 variants in each sorted population 126
were PCR amplified and sequenced, and DNA reads for each variant were counted. We 127 calculated a score for each variant by taking the ratio of its frequency in the GFP-positive 128 cells to its frequency in the GFP-negative cells, and normalized to the equivalently 129 calculated ratio for the WT transgene. Scores from this pilot assay were largely consistent 130 with published results for these variants (Fig.  1c,  d Table 2 ). The barcodes were amplified and 143 sequenced from the genome of the cells in the GFP-positive and GFP-negative 144 populations. The score for each variant was calculated as described above for the small-145 scale assay (Supplementary Table 4 ). Variant scores between replicates were well 146 correlated for pool1, but less so for pools 2 and 3, for which most variants scored close 147 to ln(0), indicating no depletion ( Supplementary  Fig.  2 measurements of BRCA1 function in HDR is a low number and may reflect appropriate 228 biology of the two assays. This is especially true given that the biochemical mechanism 229 affecting cell growth in the SGE assay is unknown. Of the five differences when 230 comparing the high-throughput HDR and SGE assays, C44G may be a false negative of 231 the multiplexed HDR reporter assay given that all amino acid substitutions in the cysteine 232 and histidine residues that bind zinc ions in the BRCA1 RING domain that have been 233 tested to date in singleton functional assays were damaging 12-14 , although this specific 234 C44G variant has not before been tested for HDR function. Alternatively, C44G and the 235 other discordant variants may be slightly destabilized and rescued by the expression level 236 in the HDR reporter assay, or these residues may be necessary for another function of 237 BRCA1 critical for cell survival in the SGE assay.
239
Clinical interpretations for some of the BRCA1 variants that we functionally score here 240 are reported in the ClinVar database (accessed June, 2017) 20 . Of the ~1,700 variants 241 scored here, seven were classified as benign or likely benign in ClinVar. All seven were 242 either never depleted, or depleted in only one replicate, in the multiplexed HDR assay. In 243 contrast, we tested five BRCA1 variants that are established pathogenic mutations in 244
ClinVar. Of these, four were depleted in 3 or 4 replicates in the multiplexed HDR assay.
245
The fifth pathogenic variant, R71G, had WT-like DNA repair activity in our data, a result 246 consistent with previous HDR reporter assays 15 . R71G causes a defect in RNA splicing 18 , 247 which as discussed above we do not expect to be detectable in our assay (Fig.  3e ).
249
In summary, we observe strong concordance between variants depleted in 0-1 replicates 250 in our assay and benign status in ClinVar or WT-like function in other assays;; as well as 251 between variants depleted in 3-4 replicates in our assay and pathogenic status in ClinVar 252 or loss-of-function in other assays. We therefore concluded that the number of replicates 253 in which a variant is found depleted is a reasonable proxy for its functionality, and term 254 these as "depletion scores" (range 0-4, Supplementary Table  5) . 255 256
Depletion scores identify damaging BRCA1 variants 257
Depletion scores for all variants passing the read-count threshold in at least three 258
replicates are shown in the form of a sequence-function map in Fig. 4a . 100% of the 259 damaging amino acid substitutions (dark red) were observed in the first 98 amino acids 260 which comprises the RING domain, whereas residues 99-302 strongly tended to tolerate 261 amino acid substitutions. Nonsense mutants, indicated with the asterisk on the bottom 262 row were for the most part non-functional. Three of these nonsense mutants were scored 263 as functional (codons 289, 290, and 291), and we consider these to be false negatives.
264
The distribution of variants indicates that the degenerate positions in the mutagenic 265 oligonucleotides used to make the site-saturation mutagenesis libraries contained a much 266 higher fraction of guanines than the 1:1:1:1 ratio of the four nucleotides specified for the 267 synthesis (see Methods). Thus, codons containing guanine in the first or second position 268 (particularly glycine, arginine, alanine and valine) are the most highly represented. Since 269 the highest representation of substitutions was to glycine, we mapped the number of 270 times each substitution to glycine was found depleted in replicate experiments to the 271 solution structure of the BRCA1 and BARD1 RING domain dimer 23 (Fig. 4b) . Amino acids 272 positions that were the most intolerant to substitution were either buried in the interior of 273 the 4-helix bundle, which acts as the BARD1 interface, or in the loops that coordinate zinc 274 ions.
276
We examined the depletion scores of 77 BRCA1 variants that are ambiguously classified 277 in ClinVar (VUS or conflicting reports of pathogenicity) to predict their functional impact.
278
Of 66 variants tested in the multiplexed HDR reporter assay that were classified as VUS 279 in ClinVar, three (V11G, C47G and I68R) had a depletion score of 3-4 and are thus likely 280 nonfunctional for HDR. Of 12 variants that have conflicting interpretations of pathogenicity 281 in ClinVar, four (M18T, T37R, C39F and H41L) were nonfunctional in the DNA repair 282 assay (Fig.  3e) . These seven variants, all ambiguous in ClinVar and nonfunctional in our 283 assay, are either at positions that coordinate zinc ions (C39F, C47G, H41L), at positions 284 within the zinc-finger loops (T37R and I68R) or to have side chains in the interior of the 285 4-helix bundle (V11G and M18T). Most known pathogenic missense mutations map to 286 these same structural features. Of note, the four variants currently listed in ClinVar as 287 having conflicting interpretations of pathogenicity and nonfunctional here were interpreted 288 in the past as likely pathogenic or pathogenic 3 . 289 290
The remaining 70 variants that are ambiguously classified in ClinVar (VUS or conflicting 291 reports of pathogenicity) have a low depletion score in our assay. Of these, 60 lie outside 292 of the RING domain where we did not identify any damaging amino acid substitutions.
293
The 10 variants found within the structured RING include V11A, a conservative amino 294 acid substitution inside the 4-helix bundle, and I90T, whose sidechain points out of the 295 helix. T77M and T97A are substitutions to the amino acids that abut the helices and may 296 not affect BARD1 binding;; however, other changes at T97 are not tolerated (Fig. 4a) . I42L 297 and M48V are in the RING loops but are conservative changes and therefore may be 298 tolerated;; E29G, E33A, G57R and P58A are also in the loops, but their side chains point 299 away from the interior of the structure which may be why they are tolerated. Therefore, failed reactions and uneven mixing of the PCR products caused loss of all or 328 most substitutions at some positions (Fig.  4a) . Second, a strong guanine bias at each 329 degenerate nucleotide position during oligonucleotide synthesis led to a bias in the 330 encoded amino acids (Fig. 4a) . We anticipate that if the distribution of variants in the 331 library were more uniform, we would be able to query more variants per experiment, with 332 a theoretical maximum of ~4,000 variants per experiment under ideal conditions, at our 333 current number of sorted cells. Alternative approaches using array-derived 334 oligonucleotides may create more uniformly distributed variant libraries 26, 27 . It may also 335 be useful to limit the number of amino acid changes to those accessible by single 336 nucleotide changes, as these are the missense variants relevant to human disease. 337
However, this limitation would also reduce the information content of the multiplexed 338 experiments.
340
In addition to improving library uniformity, restricting the number of barcoded variants in 341 each multiplexed HDR reporter experiment should result in more variants that pass the 342 read-count filter. For example, a higher percentage of variants passed the read count 343 threshold in pool2 (50%, on average) than pool1 (29%) and pool3 (31% The depletion score for each variant is the count of experimental replicates in which it 404 was found depleted from the functional population. Each position in BRCA1(2-302) is 405 arranged along the x-axis, the position of the RING domain is diagrammed above. 
Methods

443
All enzymes unless specifically mentioned were purchased from New England Biolabs.
444
Primer sequences can be found in Supplementary  Table  3.  445   446 Creating the HeLa DR-FRT cell line: A description of the HeLa-DR cell line can be found 447 here 13 . To create a FLP-in version of HeLa DR, we stably integrated into the cells a flipase 448 recognition target (FRT) sequence using the pFRT/lacZeo plasmid (Thermo Fisher).
449
Zeocin resistant clones that had a single integration site detected by Southern blot were 450 tested for high activity integration sites using the mammalian β-galactosidase activity 451 assay (Gal-Screen, ThermoFisher has reduced activity at 37°C, four to eight hours post transfer, the cells were moved from 525 a 37°C humidified incubator to a 30°C humidified incubator for 24 hours. The cells were 526 then returned to 37°C for an additional 24 hours. Approximately 72 hours after the initial 527 transfection, the cells were trypsinized and transferred to twenty 15 cm plates containing 528 selection media (50% fresh DMEM supplemented with 10% fetal bovine serum, 50% filter 529 sterilized conditioned media and hygromycin B at 550 µg/mL). Hygromycin resistant cells 530 are selected at 37°C for 24 hours. The cells are washed with sterile phosphate buffered 531 saline (PBS) and the selection media is replaced after the first 24 hours and again every 532 48 hours until cell colonies are visible without a microscope (about 14 days). Colonies 533 were then counted, trypsinized, resuspended in 20 mL culture media, and mixed 534 thoroughly, colony counts can be found in Supplementary Table 1. 15 ml of the 535 resuspended cells were frozen in 1 mL aliquots. 5 mL of resuspended colony mixture 536 was plated onto three 15 cm plates (3 mL, 1.5 mL, 0.5 mL) and incubated for 24 hrs. The 537 plate that was closest to a confluent monolayer of cells was passaged. The cells were 538 passaged for an additional two weeks before performing HDR reporter experiments to 539 assure loss of the unintegrated BRCA1 expression plasmid. 540 541 HDR reporter assays, sorting, gDNA prep: HDR reporter assays and FACS sorts were 542 performed for each of the three BRCA1 variant libraries in quadruplicate. A confluent 10 543 cm plate of HeLa BRCA1 variant cell line was trypsinized and resuspended in 10 mL of 544 culture media. 65 µl of the suspension was plated in each of 48 wells across two 24-well 545 tissue culture plates. 24 hours later, each well was transfected with 30 pmol of siRNA and 546 1.5 µl Oligofectamine (ThermoFisher). Oligofectamine was diluted with 6 µl Opti-MEM 547
and siRNA was diluted with 25 µl Opti-MEM for 5 minutes. The dilutions were then 548 combined and incubated for an additional 30 minutes. The transfection mixture was then 549 applied directly to the cells. 24 hours later, the cells were trypsinized and transferred to 550 four 6-well tissue culture plates, then incubated for another 24 hours. Each well was then 551 transfected with 50 pmol of siRNA, 3 µg pCBASceI (for I-SceI expression), and 3 µl 552
Lipofectamine 2000. Plasmid and siRNA were diluted in 125 µl Opti-MEM and 553
Lipofectamine was diluted in 125 µl Opti-MEM, then incubated for 5 minutes. The dilutions 554 were combined and incubated for an additional 20 minutes. The transfection mixture was 555 then applied directly to cells. Four to six hours later, the culture media was replaced with 556 fresh media. BRCA1 3'UTR siRNA, BRCA1 coding sequence siRNA and control siRNA 557 were used in both rounds of transfection. After 24 hours, one well of cells treated with 558 each condition was analyzed for GFP expression using flow cytometry to confirm 559 transfection efficiency. If cells treated with control siRNA and 3'UTR siRNA fell within 7-560 9% and 4-7% GFP+ cells respectively, and cells treated with BRCA1 coding sequence 561 siRNA were 1-2% GFP+, the experiment would proceed. 72 hours post-transfection, the 562 cells were pooled according to treatment and sorted using fluorescent activated cell 563 sorting (FACS) using an Aria IIu instrument. sample. The ratio of the frequency of each variant in the GFP positive population over its 605 frequency in the GFP negative population was calculated. That ratio for each variant was 606 then normalized to the GFP+/GFP- ratio for the wild-type sequence at ln(GFP+/GFP-) = 607 0. Variants with multiple amino acid substitutions were removed from further analysis. 608 609
To construct the binary, functional / nonfunctional classifier for variants, we first 610 determined that the standard deviation of the score decays according to read count in a 611 way that can be modeled by a log 10 -log 10 curve. We then modeled the decay of the 612 standard deviation of scores from the control siRNA experiment. Next, we applied that 613 model to the standard deviation of scores from the BRCA1 siRNA experiment and 614 calculated a p-value and an FDR-adjusted q-value for each variant to determine if it was 615 similar to the control siRNA experiment (q > 0.05) or significantly different from control 616 experiment (q <0.05). Finally, we determined where the false positives in the control 617 experiments occurred along the continuum of read counts to assign a read-count 618 threshold for the BRCA1 siRNA condition. A read-count threshold is usually part of the 619 heuristic applied to remove noise due to stochastic dropout from deep mutational 620 scanning data 16 . We removed variants with below that read count threshold from further 621 analyses. These analyses are performed using R studio, an R markdown file containing 622 all data manipulations is supplied as Supplementary File 1. 623 624
The depletion score represents the number of replicates in which a variant was found to 625 be depleted from the BRCA1 siRNA GFP-positive population. Only variants that had been 626 
replicates depleted no data 
